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Summary
Background:  The Azorean population presents the highest standardized mortality rate for
cardiovascular diseases (CVD) when compared to mainland Portugal and other populations. Since
thrombosis is a common cause of CVD, we assessed four polymorphisms in three thrombotic risk
genes – F5 (G1691A), F2 (G20210A) and MTHFR (C677T, A1298C), in 469 healthy blood donors
from São Miguel Island (Azores). We also analysed the CYP2C9 (C430T, A1075C) and VKORC1
(G1639A) variants in fifty-eight individuals with predisposition to thrombosis (possessing at least
one variation in F5 or F2 genes and one in MTHFR) to evaluate their warfarin drug response genetic
profiles.
Results: Among the 469 individuals, the data showed that thrombotic risk allele frequencies –
1691A (4.9%), 20210A (1.8%), 677T (41.7%) and 1298C (24.8%) – were similar to other
Caucasians, but significantly different from mainland Portuguese (χ2, p < 0.001). The combined
analysis of these variants identified twenty-two different genetic profiles (genotype order: F5, F2,
MTHFR C677T and A1298C). Complete homozygosity for all wild-type alleles (GG GG CC AA)
was present in 11.7%, being GG GG CT AA (22.4%) the most frequent profile. The results also
demonstrated that 12.4% (58 out of 469) of São Miguel islanders have increased genetic
predisposition to thrombosis. Subsequently, we evaluated these individuals for their warfarin
response genetic profiles. The data showed that seven out of fifty-eight individuals are poor
metabolizers (two with CYP2C9*2/*2 and five with CYP2C9*2/*3 genotypes). VKORC1
polymorphism analysis identified twelve individuals (20.7%) with AA genotype, who probably will
require lower doses of warfarin. The joint analysis of CYP2C9 and VKORC1 revealed that 79.3% (46
out of 58) of the individuals carry at least one polymorphism in these genes. Within these, twenty-
five individuals (43.1%) need intermediate and/or low doses of warfarin, if treatment is started.
Conclusion: The present study demonstrated, for the first time, that São Miguel, and possibly the
Azores population, shows significant differences on allele frequencies of thrombotic risk factors
when compared to mainland Portugal. This research constitutes a primary approach for future
studies on CVD, as well as for the implementation of warfarin dosing protocols using the patient's
genotypic information.
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Background
Cardiovascular diseases (CVD) are complex disorders that
include dysfunctional conditions of the heart, arteries and
veins. Within these diseases, thrombosis is the third most
common cardiovascular event worldwide [1]. It can derive
from: i) genetic factors; ii) acquired changes in the clotting
mechanism; and iii) more commonly, interaction
between the two factors described above [2-4]. The main
hereditary form of thrombosis is caused by the G1691A
variation in the factor V Leiden gene (F5; 1q23), resulting
in resistance to activated protein C (APC). In the coagula-
tion biochemical pathway, APC prevents blood clots from
growing extensively large, by inactivating coagulation fac-
tor V (encoded by F5). The G1691A variation may
increase the risk for thrombosis by 8 and 91 in hetero-
zygous and homozygous states, respectively [5]. Accord-
ing to Poort et al. [6], prothrombin (F2; 11p11-q12)
represents the second most important inherited throm-
botic risk factor. A single base substitution (G20210A) in
the F2 3'-untranslated region causes elevated plasma pro-
thrombin levels. The same authors reported a 2.8-fold
increase risk for venous thrombosis in heterozygous and
homozygous variant individuals [6]. Other reported gene
involved in thrombosis, the methylenetetrahydrofolate
reductase (MTHFR; 1p36.3), includes two variants –
C677T and A1298C [7]. The 677T alters the protein's
folate binding site and lowers the enzymatic activity of
MTHFR. As consequence, patients have elevated plasma
levels of total homocysteine (tHcy) [8]. The 1298C variant
also decreases the enzymatic activity of MTHFR, which is
more pronounced in homozygous variant than in hetero-
zygous state [8]. According to Heijer et al. [9], individuals
with the 677TT genotype show a 15% (OR = 1.1; 95% CI
= 1.0–1.3) increased risk for venous thromboembolism
(VTE) in Europe. Additionally, Klerk et al. [10] reported an
OR of 1.3 (95% CI = 1.1–1.5) for the 677CT genotype.
The genetic characterization of the individual's potential
risk for developing thrombosis and response to drugs is
essential in clinical follow-ups, as well as for medical pre-
scription. Warfarin is one of the most widely used antico-
agulant drug, which requires a thorough risk-benefit
analysis since the dose prescribed should avoid hemor-
rhagic complications and achieves suppression of throm-
bosis [11]. The administrated drug is a racemic mixture of
S- and R-enantiomers, having S- the majority of the thera-
peutic effect [12]. Warfarin pharmacogenetic studies dem-
onstrated that variants in the CYP2C9 (Cytochrome P450
2C9) and VKORC1 (Vitamin K epoxide reductase complex
subunit 1) genes account for approximately 50–60% of
drug dosing variability [13,14]. Cytochrome P450 2C9 is
the major enzyme responsible for metabolising the active
S-enantiomer [12]. Although there are many polymor-
phisms in CYP2C9, the most frequent variants are:
CYP2C9*1 (Arg144/Ile359, wild-type), CYP2C9*2
(Arg144Cys) and CYP2C9*3 (Ile359Leu). These last two
are associated with decreased metabolic efficiency of the
CYP2C9 enzyme and increased risk of bleeding when
administrated initial dosages of warfarin [15]. A G>A var-
iation at position 1639 in the promoter region of the
VKORC1 gene results in decreased mRNA transcription
and increased sensitivity to warfarin inhibition of hepatic
synthesis of functional vitamin K-dependent coagulation
factors [13]. Rieder et al. [13] studied VKORC1 polymor-
phisms and classified individuals according to warfarin
dose requirements into distinct groups: high (GG), inter-
mediate (GA) and low (AA).
The Azores population presents the highest standardized
mortality rate caused by CVD when compared to main-
land Portugal (Portuguese General Directorate of Health)
[16] and other populations. Since thrombosis is a known
cause of CVD, the present research aims to assess, in the
São Miguel healthy population, the allelic variants and
genotypes of three genes – F5, F2 and MTHFR – involved
in blood clot formation. Moreover, in the individuals
with predisposition to thrombosis, we evaluated the phar-
macogenetic profile for warfarin, by characterizing
CYP2C9 and VKORC1 polymorphisms. This information
is important for the implementation of warfarin pre-pre-
scription genotyping with the goal of performing individ-
ualized treatment.
Materials and methods
Population sample
The population sample comprised a group of 469 São
Miguel Island blood donors from the anonymized Azo-
rean DNA bank located in the main Hospital of Azores
archipelago, Portugal [17]. São Miguel, the largest island
in this archipelago, has 131,609 inhabitants (54.4% of
the Azoreans; 2001 Census, Portugal National Institute of
Statistics) [18]. In this group we analysed four polymor-
phisms in three thrombotic predisposition genes – F5
(G1691A), F2 (G20210A) and MTHFR (C677T, A1298C).
After evaluating the genetic variants in the aforemen-
tioned genes, we selected a subset of individuals who met
one of the following criteria: 1. one variant in F5 and one
in MTHFR (fourty-three individuals); 2. one variant in F2
and one in MTHFR (fifteen individuals) and 3. one vari-
ant in F5, F2 and MTHFR (zero individuals). These criteria
were chosen to restrict the sample to individuals who
would have a higher genetic risk for a thrombotic event,
and hence fifty-eight individuals were analysed for
CYP2C9 and VKORC1 polymorphisms.
Genotyping of F5 and MTHFR polymorphisms
F5 and MTHFR polymorphisms (Table 1) were evaluated
by polymerase chain reaction – restriction fragment
length polymorphism (PCR-RFLP), using three different
restriction enzymes: MnlI, HinfI and MboII (New EnglandThrombosis Journal 2009, 7:9 http://www.thrombosisjournal.com/content/7/1/9
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Biolabs, Beverly, MA, USA). The genotyping protocol for
the detection of the F5 polymorphism and MTHFR vari-
ants was adapted from Kumar et al. [19] and Skibola et al.
[20], respectively.
Genotyping of F2, CYP2C9 and VKORC1 polymorphisms
The genetic tests used for F2, CYP2C9 and VKORC1 (Table
1) were PTH StripAssay™ and PGX-Thrombo StripAssay™
kits (ViennaLab-Labordiagnostika GmbH-Austria),
according to the manufacturer's recommendations. These
assays are based on reverse hybridization system, using
biotin-labelled amplification products to a parallel array
of allele-specific oligonucleotides immobilized on a
membrane test strip.
Statistical Analysis
Allele frequencies were obtained by direct count. Hardy-
Weinberg equilibrium was calculated using the Arlequin
software v.3.20. This software was used to assess maxi-
mum likelihood genetic profiles for thrombotic risk fac-
tors, through the expectation maximization algorithm, an
iterative procedure from multilocus genotype data with
unknown gamete phase. Allele and genotype frequencies
were compared between São Miguel islanders and main-
land Portuguese by χ2 test using the SPSS software v.17.0.
A p < 0.05 was considered statistically significant.
Results
Allele and genotype frequencies of thrombotic genetic risk 
factors
Allele and genotype frequencies of F5  (G1691A),  F2
(G20210A) and MTHFR  (C677T, A1298C) polymor-
phisms were assessed in 469 healthy individuals from São
Miguel Island, Azores (Table 2). All markers were in
Hardy-Weinberg equilibrium. The F5 variant 1691A fre-
quency was 4.9%, whereas the heterozygous genotype
(1691GA) was present at 9.8% (fourty-six individuals).
We did not detect 1691AA individuals. The results on the
F2  analysis show an allele frequency of 1.8% for the
20210A variant. Although this polymorphism is also
uncommon in other populations, one homozygous vari-
ant individual (0.2%) and fifteen heterozygous (3.2%)
were observed in the present study. The frequency of the
variant alleles in MTHFR (677T and 1298C) was 41.7 and
24.8%, respectively. Overall, 17.9% are 677TT (eighty-
four individuals), and 6.0% present the 1298CC genotype
(twenty-eight individuals).
Twenty-two different genetic profiles for F5,  F2  and
MTHFR (order in genotype profile) were observed in São
Miguel's population (Figure 1). The frequency of individ-
uals who present a wild-type genotype for all polymor-
phisms (GG GG CC AA; 11.7%) was almost half of the
major profile (GG GG CT AA; 22.4%), differing in hetero-
zygosity for MTHFR  677CT. Statistical analysis of the
combined genotypes demonstrated that there is no signif-
icant difference between the present distribution and the
hypothetical obtained by Arlequin software (χ2, p = 0.99).
No heterozygous or homozygous profiles for all four var-
iants were observed. Almawi et al. [21], reported an OR of
10.5 (95% CI = 4.3–25.3) or 6.3 (95% CI = 1.5–26.0) for
joint occurrence of the F5 G1691A or F2 G20210A with
MTHFR 677TT genotype, respectively, enhancing the risk
for deep vein thrombosis (DVT). Based on this criterion,
fifteen (3.2%, F5/MTHFR) and two individuals (0.4%, F2/
MTHFR) have higher risk for DVT development (Figure 1
– asterisk character; Table 3 – bold characters). In general,
the joint analysis of all four variants demonstrated that
12.4% of the total sample (58 out of 469) has increased
predisposition to thrombosis development.
The comparison of allele frequencies of the thrombotic
genetic risk factors – F5, F2 and MTHFR – in different pop-
ulations, including São Miguel, is depicted in Figure
2[6,22-38]. F5 G1691A varies from as low as 0.67% (Afri-
can-American) to 4.9% (São Miguel Island). This trend is
not evident for F2 G20210A, where the values present a
lower range, from 0.3% for African-American to 2.6% for
Spanish. African populations showed the lowest fre-
quency for MTHFR variants. Taken together, the results
Table 1: Main characteristics of the seven genetic variants analysed in this study
Polymorphism Allele variant Amino acid change Gene
Location Position NCBI dbSNP rs#
Factor V Leiden 1691G>A R506Q 1q23 Exon 10 rs6025
Prothrombin 20210G>A NA 11p11-q12 3'-UTR rs1799963
MTHFR 677C>T A222V 1p36.3 Exon 5 rs1801133
1298A>C E429A 1p36.3 Exon 8 rs1801131
CYP2C9*2 430C>T R144C 10q24.1 Exon 3 rs1799853
CYP2C9*3 1075A>C I359L 10q24.1 Exon 7 rs1057910
VKORC1 1639G>A NA 16p11.2 Promoter rs9923231
NA – not applicable; UTR – untranslated region.Thrombosis Journal 2009, 7:9 http://www.thrombosisjournal.com/content/7/1/9
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demonstrate that, in São Miguel, the frequencies for all
polymorphisms were similar to those found in Cauca-
sians.
Frequencies of pharmacogenetic variants in individuals 
with genetic predisposition to thrombosis
In order to understand warfarin pharmacogenetic profile
in the fifty-eight individuals, carriers of at least one varia-
tion in F5 or F2 genes and one in MTHFR, we studied
CYP2C9 and VKORC1 gene polymorphisms. The allele
frequencies for CYP2C9*2 and CYP2C9*3 were 15.5 and
10.3%, respectively (Table 2). Five genotypes were
observed: CYP2C9*1/*1 (60.3%), CYP2C9*1/*2
(15.5%), CYP2C9*1/*3 (12.1%), CYP2C9*2/*2 (3.5%)
and CYP2C9*2/*3 (8.6%). The data indicate that 39.7%
will require intermediate and/or low warfarin mainte-
nance doses. Regarding the VKORC1 gene (G1639A), we
identified twenty (34.5%) wild-type individuals, twenty-
six (44.8%) heterozygous and twelve (20.7%)
homozygous variant, corresponding to an allele fre-
quency of 43.1% for 1639A (Table 2). These results sug-
gest that 65.5% need intermediate and/or low doses of
warfarin.
The majority of individuals with a genetic predisposition
to thrombosis (79.3%, 46 out of 58) carry at least one pol-
ymorphism in the genes involved in the metabolism of
warfarin (Table 3). Moreover, the joint analysis of
CYP2C9  and  VKORC1  identified a total of thirty-three
(57%) individuals that probably will require high doses
of warfarin (genotypes: *1*1-GG→twelve individuals,
*1*1-GA→fourteen, *1*2-GG→four and *1*3-GG→
three), and eight (13.8%) will need lower doses (geno-
types: *1*2-AA→one individual, *1*3-AA→one, *2*2-
Table 2: Allele and genotype frequencies for thrombotic risk factors and for warfarin pharmacogenetic variants in São Miguel 
population
Polymorphism Allele na Freq. Genotype nb Freq.
Thrombotic risk variants in general population (N = 469)
Factor V Leiden
1691G>A G 892 0.951 GG 423 0.902
A 46 0.049 GA 46 0.098
AA 0 0.000
Prothrombin
20210G>A G 921 0.982 GG 453 0.966
A 17 0.018 GA 15 0.032
AA 1 0.002
MTHFR
677C>T C 547 0.583 CC 162 0.345
T 391 0.417 CT 223 0.475
TT 84 0.179
1298A>C A 705 0.752 AA 264 0.563
C 233 0.248 AC 177 0.377
CC 28 0.060
Warfarin pharmacogenetic variants in individuals with predisposition to thrombosis (N = 58)
CYP2C9
430C>Tc C 98 0.845 *1/*1 35 0.603
T 18 0.155 *1/*2 9 0.155
*2/*2 2 0.035
1075A>Cc A 104 0.897 *1/*3 7 0.121
C 12 0.103 *2/*3 5 0.086
*3/*3 0 0.000
VKORC1
1639G>A G 66 0.569 GG 20 0.345
A 50 0.431 GA 26 0.448
AA 12 0.207
a Number of chromosomes
b Number of alleles
c*1*1 (430CC/1075AA), *1*2 (430CT/1075AA), *1*3 (430CC/1075AC), *2*2 (430TT/1075AA), *2*3 (430CT/1075AC) and *3*3 (430CC/1075CC)Thrombosis Journal 2009, 7:9 http://www.thrombosisjournal.com/content/7/1/9
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GA→two, *2*3-GA→one and *2*3-AA→three). The
remaining seventeen individuals (29.3%) present one of
the following genotypes: *1*1-AA→nine individuals,
*1*2-GA→four, *1*3-GA→three and *2*3-GG→one,
where all of them will possibly necessitate intermediate
doses. In summary, twenty-five individuals (43.1%) will
need intermediate and/or low doses of warfarin, if treat-
ment is started.
Discussion
In the general population, individuals may develop
thrombosis due to multiple risk factors, acquired and
genetic. Clearly, acquired factors (smoking, high choles-
terol, obesity, etc.) are more frequent and combined with
a genetic predisposition further enhance the risk of a
thrombotic event. In the present study, the results
obtained from 469 São Miguel healthy individuals dem-
onstrate that approximately 5% have the F5 1691A allele,
the most common hereditary risk factor. Although the fre-
quency found for São Miguel is higher than mainland Por-
tuguese, 1% [22], we did not detect homozygous variant
individuals. Nonetheless, the data suggest that São Miguel
islanders have an increased predisposition to thrombosis
and, most probably for CVD. Another inherited cause of
thrombosis is the G20210A polymorphism in the F2
gene. According to Bosler et al. [39], this variant is weak
but a consistent risk factor for DVT and for development
of CVD, although to a lesser degree than F5 [4]. The F2
Combined genotypes for thrombotic risk factors – F5, F2 and MTHFR – in São Miguel population Figure 1
Combined genotypes for thrombotic risk factors – F5, F2 and MTHFR – in São Miguel population. Twenty-two dif-
ferent genetic profiles were obtained. Bold characters (blue and black) indicate nucleotide changes compared to the wild-type 
allele. The asterisk (*) represents the combination of the F5 G1691A or F2 G20210A with MTHFR 677TT genotype. Blue bars 
correspond to the subset of fifty-eight individuals with genetic predisposition to thrombosis selected for warfarin pharmacoge-
netic study.
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results show a lower frequency, 1.8%, when compared to
mainland Portugal, 2.5% [22].
The most general form of genetic hyperhomocysteinemia
results from the MTHFR C677T variant, which has a rela-
tively high frequency throughout the world and is consid-
ered a low risk factor for vascular diseases [9]. In São
Miguel population, MTHFR  677T shows an allelic fre-
quency of 41.7%, very similar to Europeans (Figure 2).
According to Almawi et al. [21], MTHFR 677TT genotype
when associated with F5 or F2 increases the risk of DVT
[20]. Based on these genotypes, the data suggests that
3.6% (seventeen individuals) of the São Miguel Island
population may have higher risk for developing a throm-
botic event. Regarding the 1298C variant, the results were
in agreement with those reported by other studies (Figure
2), where the polymorphism is also common. We can
hypothesise that if the 1298CC individuals have higher
Table 3: Warfarin pharmacogenetic profile obtained in the fifty-eight individuals, carriers of at least one variation in F5 or F2 genes and 
one in MTHFR
Thrombotic risk factors Warfarin pharmacogenetics
F5 F2 MTHFR CYP2C9 VKORC1
N (%) 1691G>A 20210G>A 677C>T 1298A>C 430C>T 1075A>C 1639G>A
1 (1.7) GA GG TT AA TT AC GA
1 (1.7) GA GG TT AA CT ACA A
1 (1.7) GA GG CC AC CT AC GA
2 (3.5) GA GG CT AA CT AC GA
1 (1.7) GA GG CC AC CT AC GG
1 (1.7) GG GA CT AC CC ACA A
1 (1.7) GA GG CC CC CC AC GA
1 (1.7) GA GG CT AC CC AC GA
1 (1.7) GG GAT T AA CC AC GA
1 (1.7) GA GG CC AC CC AC GG
2 (3.5) GA GG CT AA CC AC GG
1 (1.7) GA GG TT CC TT AA GA
1 (1.7) GA GG CT AA CT AA AA
1 (1.7) GA GG CT AC CT AA GA
1 (1.7) GA GG TT AA CT AA GA
2 (3.5) GG GA CT AC CT AA GA
1 (1.7) GG GA CT AA CT AA GG
2 (3.5) GA GG CT AA CT AA GG
1 (1.7) GA GG TT AA CT AA GG
2 (3.5) GA GG CC AC CC AA AA
1 (1.7) GA GG CT AA CC AA AA
3 (5.2) GA GG TT AA CC AA AA
1 (1.7) GG GA CC AC CC AA AA
1 (1.7) GG GA CT AC CC AA AA
1 (1.7) GG GAT T AA CC AA AA
2 (3.5) GA GG CC AC CC AA GA
1 (1.7) GA GG CT AA CC AA GA
2 (3.5) GA GG CT AC CC AA GA
4 (6.9) GA GG TT AA CC AA GA
1 (1.7) GG AA CC AC CC AA GA
1 (1.7) GG GA CC AC CC AA GA
1 (1.7) GG GA CC CC CC AA GA
2 (3.5) GG GA CT AA CC AA GA
2 (3.5) GA GG CC AC CC AA GG
3 (5.2) GA GG CT AA CC AA GG
2 (3.5) GA GG CT AC CC AA GG
1 (1.7) GG GA CC CC CC AA GG
1 (1.7) GG GA CT AA CC AA GG
3 (5.2) GA GG TT AA CC AA GG
Italic characters indicate nucleotide changes considering the wild-type allele and in bold illustrate carriers of the F5 G1691A or F2 G20210A with 
MTHFR 677TT genotype conferring high thrombotic risk.Thrombosis Journal 2009, 7:9 http://www.thrombosisjournal.com/content/7/1/9
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plasma homocysteine levels, they will present an
enhanced risk for thrombosis.
The joint analysis of all variants demonstrated that 12.4%
of the total sample (58 out of 469) has increased predis-
position to thrombosis development. In addition, com-
parison of allele frequencies for all thrombotic risk factors
between São Miguel and mainland Portugal revealed sta-
tistically significant differences (χ2, p < 0.001). Family-
based investigation tends to have biased relative risk esti-
mation, because oversampling of affected individuals is
normally present. Therefore, the genetic characterization
of disease variants in the general population is important
to correct this potential bias. Consequently, the present
research will aid the clinical follow-ups of patients with
recurrent thrombotic events.
In today's medicine, the association between pharmaco-
genetics and drug therapy represents an important tool to
treat or control complex diseases. Drug treatment is based
on the assumption that a particular dose will yield a pre-
defined blood concentration in circulation and, thereby,
establish the desired therapeutic effect [40]. Recent inves-
tigations clearly demonstrate an association between war-
farin dose requirements and genetic variations in CYP2C9
and VKORC1 [14]. Here, we analysed 58 individuals with
genetic predisposition to thrombosis defined by at least
one variation in F5 or F2 genes and one in MTHFR. The
results obtained show that approximately 60.3% present
the genotype CYP2C9*1/*1, while the remaining have
CYP2C9*2 and CYP2C9*3 variants. The presence of two
copies of the active CYP2C9*1 alleles represents the nor-
mal metabolic capacity – extensive metabolizers (EMs) -,
indicating that individuals with this genotype require the
highest warfarin maintenance doses [41].
Considering São Miguel islanders with genetic predisposi-
tion to thrombosis, the data of CYP2C9*2 and CYP2C9*3
alleles demonstrate a close similarity with different Euro-
pean populations [42-44]. Individuals who are hetero-
Allele frequencies of the thrombotic risk factors – F5 (G1691A), F2 (G20210A) and MTHFR (C677T, A1298C) – in different  populations, including São Miguel Figure 2
Allele frequencies of the thrombotic risk factors – F5 (G1691A), F2 (G20210A) and MTHFR (C677T, A1298C) – 
in different populations, including São Miguel.
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zygous (CYP2C9*1/*2 and CYP2C9*1/*3) represent a
middle range of metabolic activity – intermediate metab-
olizers, IMs [43,44]. The results reveal that, within the
fifty-eight subset, 15.5 and 12.1% are IMs, respectively.
The CYP2C9*2 and CYP2C9*3 variants have less activity
and metabolize warfarin more slowly. Individuals with
one or two of these variations – poor metabolizers (PMs)
– have an enhanced response to warfarin, as well as an
increased risk of bleeding when beginning and during
treatment if not genotyped previously [44]. We observed
that seven out of fifty-eight individuals are PMs (two with
CYP2C9*2/*2 and five with CYP2C9*2/*3 genotypes;
Table 2). Detecting genetic variations in drug-metaboliz-
ing enzymes is useful for identifying individuals who may
experience adverse drug reactions (ADRs) with conven-
tional medication doses. Those who are CYP2C9 PMs may
exhibit different pharmacokinetics than wild-type indi-
viduals if they are medicated with warfarin. Conse-
quently, these individuals possibly will require non-
conventional doses of drugs that need CYP2C9 enzyme
for biotransformation [45].
Polymorphisms within VKORC1, a target of warfarin inhi-
bition, may explain 23% of this drug dosage variability
[13]. Rieder and colleagues [13] divided individuals into
warfarin high-dose for 1639GG genotype, intermediate-
dose for 1639GA and low-dose for 1639AA. This variabil-
ity is attributed to the fact that the variant lies within the
VKORC1  promoter, potentially resulting in decreased
transcription of the gene product. In general, the results
suggest that 65.5% of the fifty-eight individuals with pre-
disposition to thrombosis will require intermediate and/
or low doses of warfarin, if treatment is started. Personal-
ized medicine relies on data based on the human genome
and disease biology characterization for the development
of preventive, diagnostic, and therapeutic strategies that
target the underlying determinants of disease in popula-
tions with specific molecular profiles [46]. For this reason,
the knowledge obtained from the pharmacogenetic pro-
file in the São Miguel's general population is and will be
important for the development of patient's individualized
therapy, mainly for those who have difficulty to stabilize
the warfarin dose.
Conclusion
The identification of hereditary risk factors, with appropri-
ate clinical evaluation will allow the informed patient and
physician to work together for effective management of
thrombosis and prevention of subsequent thrombotic
events. The present study demonstrated, for the first time,
that São Miguel, and possibly the Azores population,
shows significant differences on allele frequencies of
thrombotic genetic risk factors when compared to main-
land Portugal. This research constitutes a primary
approach for future studies on CVD, as well as for the
implementation of warfarin dosing protocols using the
patient's genotypic information.
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